|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||68.35 - 70.97|
|52 Week Range||30.04 - 92.18|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||103.94|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.86|
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna reinforce the utility of the Oncotype DX Breast Recurrence Score® test to optimize chemotherapy recommendations in patients with early-stage breast cancer with or without lymph node involvement. The important role of genomic testing to optimize patient outcomes in early-stage breast cancer was discussed in a debate between leading international breast cancer specialists during the St. Gallen Conference.
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genomic Health stock toppled Thursday after the company offered a big beat on fourth-quarter sales, but earnings were mixed. An analyst says investors are nitpicking gross margins.
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 20) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Gossamer ...
Synopsys signaled a breakout after topping views, one of four top stocks moving on earnings. Nike fell after a top college basketball player injured himself as his Nike shoe disintegrated.
Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had profit of 23 cents. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results topped Wall Street expectations. ...
Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basis and $39.7M on a Non-GAAP Basis Achieved 14th Consecutive Quarter of ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...